Author of

• 20154

  +

  P1.05 - Early Stage NSCLC (ID 691)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Early Stage NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22623

    +

    P1.05-001 - Microwave Ablation plus Recombinant Human Endostatin (Endostar) versus Microwave Ablation Alone in Inoperable Stage I Non Small Cell Lung Cancer (ID 8817)

    09:30 - 09:30  |  Author(s): X. Han
    • Abstract
    • Slides

    Background:
    Previous studies showed that inoperable stage I non small cell lung cancer (NSCLC) benefited from microwave ablation (MWA) alone. This prospective, randomized, control, single-center clinical trial aimed to determining the survival benefit of MWA plus recombinant human endostatin (endostar) compared with MWA alone.
    
    Method:
    Patients with untreated, inoperable, stage I NSCLC were recruited. They were divided into MWA/ endostar group and MWA group, the former received MWA in the primary tumor sites, followed by 2 to 4 cycles of endostar and the latter treated with MWA only. The primary endpoint was overall survival (OS), the second endpoint included disease-free survival (DFS) , and adverse events (AE).
    
    Result:
    A total of 183 patients were enrolled, involved 92 cases in the MWA/ endostar group and 91 cases in the MWA group. Up to the latest follow-up , there were 24 cases of disease progression and 6 deaths in the MWA/ endostar group, versus 49 cases of disease progression and 9 deaths in the MWA group. DFS in the MWA/ endostar group (30.0 months, 95% CI, 27.1-32.9) was significantly better than MWA group (21.3 months, 95% CI, 19.5-23.1, p = 0.000). But there was no significant difference (p = 0.471) in OS between the MWA/ endostar group (31.6 months ,95% CI, 28.3-35.0) and MWA group (30.0 months, 95% CI, 27.2-36.5). The 1, 2 and 3 year survival rates in the MWA/ endostar group were 94%, 82% and 82%, respectively, while those in the MWA group were 94%, 89% and 89%, respectively. There was no significant difference between the two groups (p=0.982, p=0.924, p=0.924). AEs of MWA were observed in 63.7 % patients. Endostar -associated AEs were not observed in the MWA/ endostar group.
    
    Conclusion:
    MWA was a safe and effective alternative treatment for patients with inoperable stage I non small cell lung cancer. MWA combined with endostar significantly improved DFS compared to MWA alone, while not increased the MWA-related complications.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.